Suggestions

Du même auteur

Lorlatinib for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer: Results of the IFCT-1803 LORLATU cohort

Archive ouverte | Baldacci, Simon | CCSD

International audience. Background: Anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) represents a rare subset of lung cancer, with specific presentation, and multiple treatment o...

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study

Archive ouverte | Girard, Nicolas | CCSD

International audience. Introduction: ROS1-rearranged (ROS1+) non-small-cell lung cancer (NSCLC) is a rare lung cancer with limited treatment options. Phase I-II studies with ROS1-tyrosine kinase inhibitors (TKIs) i...

Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial

Archive ouverte | Mazieres, Julien | CCSD

International audience. Purpose - Methods - The IFCT 1703-R2D2 trial is a multicenter, nonrandomized phase II study. Patients with -mutated, advanced NSCLC who progressed after ≥ 1 platinum-based treatment were enro...

Chargement des enrichissements...